OncoMatch/Clinical Trials/NCT06995976

Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

Is NCT06995976 recruiting? Yes, currently enrolling (Sep 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-dPNE and 18F-FDG for malignant tumour.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06995976Data as of Sep 2026Location: China

Treatment: 68Ga-dPNE · 18F-FDG — As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

68Ga-dPNE18F-FDG

Cancer type

Tumor Agnostic

Demographics

Ages ≤ 90

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06995976 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 90 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify